Most of the awarded films, including the winner of best picture, can be watched at home. Here’s a guide to catch up.
Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...
Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results